Status:
UNKNOWN
Prognostic Value of CD318 in AML at Assiut University Hospital.
Lead Sponsor:
Shimaa Arafa Ibrahim
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut University Hospital
Detailed Description
Acute myeloid leukemia (AML) is a disease with high mortality and variable prognosis . It remains a disease with a highly variable outcome depending on the exact footprint of the AML .Although many pa...
Eligibility Criteria
Inclusion
- newly diagnosed AML patients
- Age more than 18 years
- Patients not starting chemotherapy yet
- Primary AML
- Secondary AML on top of MDS or myeloproliverative noeplasms
Exclusion
- Refractory AML patients
- Relapsed AML patients
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04708444
Start Date
March 1 2021
End Date
March 1 2023
Last Update
January 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.